Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of topical LAS41007 versus Solaraze in actinic keratosis
2009-012063-33Phase 2Completed
- Sponsor
- Almirall
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LAS41007 and diclofenac in actinic keratosis (AK) (3 arms), sponsored by Almirall. Primary endpoints: Complete clinical clearance at 30 days post-treatment and Histological clearance of one pre-selected target lesion at 30 days post-treatment. Started Jun 2009; status: completed.
02
Drugs
LAS41007diclofenac
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2009-012063-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012063-33.